Two Sigma Advisers’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
Two Sigma Advisers's CGEM Position: Q1 2026 in Review
Two Sigma Advisers sold out of Cullinan Therapeutics (CGEM) in Q1 2026, closing a stake of 129,809 shares — an estimated $1.34M sold.
Two Sigma Advisers first reported a position in CGEM in Q3 2022 and held it in 9 quarters. The position peaked at $1.34M in Q4 2025. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.
- Two Sigma Advisers reported no remaining Cullinan Therapeutics position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 129,809 Cullinan Therapeutics shares in Q1 2026, an estimated $1.34M.
- Two Sigma Advisers first reported a position in Cullinan Therapeutics in Q3 2022 and held it in 9 quarters.
- Two Sigma Advisers's Cullinan Therapeutics position peaked at $1.34M in Q4 2025.
- 174 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.